Breaking News Instant updates and real-time market news.

GILD

Gilead

$64.98

-0.06 (-0.09%)

11:03
07/22/19
07/22
11:03
07/22/19
11:03

Gilead presents proof-of-concept data for GS-6207 in people living with HIV

Gilead Sciences presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function. The Phase 1b data demonstrate the first proof of concept that HIV capsid inhibition can lead to significant declines in viral load in vivo. In addition, Gilead presented preclinical data demonstrating that resistance to GS-6207 in vitro did not lead to resistance to other classes of drugs used in the treatment of HIV. These data were presented at the 10th International AIDS Society Conference on HIV Science in Mexico City. "The data presented at IAS underscore our commitment to scientific discovery, building on Gilead's legacy of transformative advances in HIV therapies," said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. "GS-6207's multi-stage mechanism of action profile is distinguishable from currently approved classes of antiretroviral agents and may provide a new avenue for the development of long-acting treatment regimens for people living with HIV." This ongoing Phase 1b trial randomized people living with HIV with no prior capsid inhibitor treatment to receive a single subcutaneous injection of GS-6207 versus placebo. The primary endpoint was maximum reduction of HIV-1 RNA through 10 days of treatment. In each dose group, mean maximum reduction in HIV-1 RNA by day 10 ranged from 1.8 to 2.2 log10copies/mL, which were all significantly greater compared with placebo. No participant experienced a serious adverse event or discontinued due to adverse events. The most common adverse events were mild to moderate reactions at the injection site, all of which were self-limiting. "This study provides the first clinical evidence that HIV capsid inhibition can lead to a significant decline in viral load and supports further evaluation of GS-6207 as a component of an effective antiretroviral regimen. In addition, a long-acting regimen can help some people living with HIV by reducing the burden of daily pill taking," said Eric Daar, MD, Chief, Division of HIV Medicine at Harbor-UCLA Medical Center and lead study author. "These early trial results support advancing GS-6207 into the next phase of clinical development to understand its role as part of long-acting HIV therapy."

  • 22

    Jul

  • 30

    Jul

  • 07

    Aug

  • 09

    Sep

GILD Gilead
$64.98

-0.06 (-0.09%)

07/15/19
JEFF
07/15/19
NO CHANGE
Target $95
JEFF
Buy
Gilead deal with Galapagos 'smart and financially savvy,' says Jefferies
Gilead Sciences (GILD) will significantly expand its pipeline in a "smart and financially savvy" expanded partnership deal with Galapagos (GLPG), Jefferies analyst Michael Yee tells investors in a research note. Gilead essentially gained options on everything in Galapagos' pipeline without having to acquire the company full out, says the analyst. He likes the deal and thinks shares of Gilead will move higher as the Street's outlook continues to improve. Yee keeps a Buy rating on Gilead with a $95 price target.
07/15/19
STFL
07/15/19
NO CHANGE
Target $188
STFL
Buy
Galapagos price target raised to $188 from $121 at Stifel
Stifel analyst Adam Walsh raised his price target on Galapagos (GLPG) to $188 from $121 after the company announced a 10-year global research and development collaboration with Gilead (GILD), calling the collaboration "a win-win to both companies." The deal, which he thinks will keep Gilead and likely other buyers from acquiring Galapagos in the next 10 years, gives the latter a deep cash position and support to expand and accelerate its research and clinical programs while it is able to maintain its "unique culture, R&D platform and proven leadership," according to Walsh, who keeps a Buy rating on Galapagos shares.
07/15/19
07/15/19
DOWNGRADE

Market Perform
Galapagos downgraded to Market Perform after Gilead deal at Raymond James
As previously reported, Raymond James analyst Dane Leone downgraded Galapagos (GLPG) to Market Perform from Strong Buy after the company and Gilead (GILD) announced a major expansion of the current collaboration agreement and partnership between the two companies. The analyst believes Galapagos' stock has now fully realized his price target by achieving his core investment thesis. He retains a positive viewpoint of Galapagos within the context of the relationship expansion with Gilead, but will be watching for how key 2020 value drivers develop over the course of the second half of 2019.
07/18/19
PIPR
07/18/19
NO CHANGE
Target $10
PIPR
Overweight
Spring Bank research agreement with NIAID 'smart,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Spring Bank (SBPH) entered into a research agreement with the National Institute of Allergy and Infectious Diseases, or NIAID, to study preclinical HBV antisense oligonucleotides. With the recent Arrowhead (ARWR) partnership with Janssen (JNJ), the analyst sees this as a "smart development program" building on Spring Bank's HBV expertise. Tenthoff also notes that Spring Bank is conducting the Phase IIb CATALYST 1 and 2 trials of 400mg inarigivir monotherapy/combination with Vemlidy in naive and suppressed HBV patients with preliminary data in the second quarter of 2020, while partner Gilead (GILD) is conducting a Phase II study of inarigivir plus Vemlidy in naive and suppressed HBV patients with initial data likely at AASLD in November. He reiterates an Overweight rating and $10 price target on Spring Bank's shares.

TODAY'S FREE FLY STORIES

01:50
09/18/19
09/18
01:50
09/18/19
01:50
General news
FX Action: »

FX Action: The USD is…

01:45
09/18/19
09/18
01:45
09/18/19
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

01:40
09/18/19
09/18
01:40
09/18/19
01:40
General news
FOMC preview: »

FOMC preview: a quarter…

01:40
09/18/19
09/18
01:40
09/18/19
01:40
General news
Fed SEP forecasts: t »

Fed SEP forecasts: the…

TBIO

Translate Bio

$11.01

0.405 (3.82%)

21:06
09/17/19
09/17
21:06
09/17/19
21:06
Syndicate
Translate Bio 9M share Spot Secondary priced at $10.00 »

Citi, Jefferies and SVB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SWK

Stanley Black & Decker

$144.45

0.73 (0.51%)

21:05
09/17/19
09/17
21:05
09/17/19
21:05
Downgrade
Stanley Black & Decker rating change at KeyBanc »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

LEN

Lennar

$53.10

-0.23 (-0.43%)

21:02
09/17/19
09/17
21:02
09/17/19
21:02
Downgrade
Lennar rating change at KeyBanc »

Lennar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

WHR

Whirlpool

$152.15

3.4 (2.29%)

21:02
09/17/19
09/17
21:02
09/17/19
21:02
Downgrade
Whirlpool rating change at KeyBanc »

Whirlpool downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TELL

Tellurian

$8.33

-0.1 (-1.19%)

20:44
09/17/19
09/17
20:44
09/17/19
20:44
Initiation
Tellurian initiated  »

Tellurian initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

20:41
09/17/19
09/17
20:41
09/17/19
20:41
Initiation
NextDecade initiated  »

NextDecade initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LINX

Linx S.A.

$7.74

0.22 (2.93%)

20:32
09/17/19
09/17
20:32
09/17/19
20:32
Recommendations
Linx S.A. analyst commentary at Jefferies »

Linx S.A. offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Conference/Events
Morgan Stanley steel analyst to hold an analyst/industry conference call »

China Materials Analyst…

GIS

General Mills

$55.03

0.48 (0.88%)

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 01

    Oct

ROAD

Construction Partners

$14.39

-0.42 (-2.84%)

20:10
09/17/19
09/17
20:10
09/17/19
20:10
Syndicate
Construction Partners 5M share Secondary priced at $14.25 »

Construction Partners 5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 18

    Sep

NVST

Envista

$0.00

(0.00%)

19:58
09/17/19
09/17
19:58
09/17/19
19:58
Syndicate
Envista 26.77M share IPO priced at $22.00 »

The deal priced inside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

INVH

Invitation Homes

$28.49

0.31 (1.10%)

19:51
09/17/19
09/17
19:51
09/17/19
19:51
Syndicate
Invitation Homes 44M share Spot Secondary priced at $28.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

, NCMI

National CineMedia

$8.35

0.25 (3.09%)

19:49
09/17/19
09/17
19:49
09/17/19
19:49
Hot Stocks
AMC Entertainment corrects 'inaccurate' statement by National CineMedia »

AMC Entertainment (AMC)…

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

NCMI

National CineMedia

$8.35

0.25 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

BA

Boeing

$384.61

5.74 (1.52%)

19:01
09/17/19
09/17
19:01
09/17/19
19:01
Hot Stocks
House panel invites Boeing CEO to testify on 737 MAX »

Chair of the House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

O

Realty Income

$75.76

1.81 (2.45%)

18:56
09/17/19
09/17
18:56
09/17/19
18:56
Hot Stocks
Realty Income raises monthly cash dividend to 22.7c per share from 22.65c »

Realty Income Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

, CDW

CDW

$113.91

0.94 (0.83%)

18:54
09/17/19
09/17
18:54
09/17/19
18:54
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: NewLink (NLNK) up…

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

CDW

CDW

$113.91

0.94 (0.83%)

TELL

Tellurian

$8.33

-0.1 (-1.19%)

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

FDX

FedEx

$173.53

-0.14 (-0.08%)

XPO

XPO Logistics

$73.83

-0.76 (-1.02%)

CHWY

Chewy

$30.20

-0.2 (-0.66%)

ADBE

Adobe

$284.59

1.54 (0.54%)

IOTS

Adesto Technologies

$10.63

-0.66 (-5.85%)

PTCT

PTC Therapeutics

$43.26

0.27 (0.63%)

TBIO

Translate Bio

$11.01

0.405 (3.82%)

ACAD

Acadia

$42.60

-1.45 (-3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 23

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 23

    Oct

  • 27

    Oct

  • 13

    Nov

  • 18

    Sep

  • 18

    Sep

  • 18

    Sep

YUMA

Yuma Energy

$5.08

-0.05 (-0.97%)

18:51
09/17/19
09/17
18:51
09/17/19
18:51
Hot Stocks
Yuma Energy enters forbearance agreement with lender YE Investment »

Yuma Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$284.59

1.54 (0.54%)

18:45
09/17/19
09/17
18:45
09/17/19
18:45
Hot Stocks
Adobe CEO: We experienced growth across all of our segments »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Oct

  • 27

    Oct

ARAY

Accuray

$3.09

-0.03 (-0.96%)

18:37
09/17/19
09/17
18:37
09/17/19
18:37
Hot Stocks
Data in Lancet Oncology discloses lower toxicity for Accuray Cyberknife patients »

Accuray announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBK

FB Financial

$38.33

-0.36 (-0.93%)

18:29
09/17/19
09/17
18:29
09/17/19
18:29
Hot Stocks
FB Financial acquires FNB Financial »

FB Financial, parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 13

    Nov

GM

General Motors

$38.28

1.07 (2.88%)

18:28
09/17/19
09/17
18:28
09/17/19
18:28
Periodicals
GM stops paying health insurance costs for union workers on strike, Reuters says »

General Motors has moved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.